NEC
19.3.2021 03:02:08 CET | Business Wire | Press release
NEC Corporation (NEC; TOKYO: 6701) and its subsidiary OCC Corporation announced today that they have completed full qualification of subsea repeaters and optical cable containing up to 24 fiber pairs (FPs) (48 fibers). This is a 50% improvement in fiber count over the 16 fiber pair systems generally available today. This development allows cable owners worldwide to construct subsea telecom cables with superior traffic capacity while reducing the cost per bit of the wet plant. This approach is fully in line with SDM (Space Division Multiplexing) system architectures. NEC’s 24 FP solution not only provides more flexibility to operate in the subsea fiber pair market, it also enables better connectivity in high-density subsea branches.
NEC achieved this milestone with minor modifications to its proven repeater and cable designs. Keeping NEC’s quadruple pump redundancy in the repeater (established more than 10 years ago) and maintaining OCC’s outstanding cabling performance has resulted in cabled attenuations lower than 0.150dB/km. Low attenuation is critical to achieve large spectral efficiency as well as lower power consumption.
“As global demands for capacity and FP flexibility continue to soar, NEC is committed to helping our customers to build up their subsea networks with large spectral efficiency, lower power consumption and large-scale subsea connectivity,” said Yoshihisa Inada, Deputy General Manager and Head of Subsea Technology Development at NEC’s Submarine Network Division. “We continue to evaluate multiple technical options to further increase capacity and reduce the cost/bit of the networks.”
OCC’s 24 fiber pair cable can be manufactured using a wide range of existing optical fibers, according to the needs of each new cable system. Each fiber can be visually identified using a field-proven combination of ring marking and conventional fiber coloring, first introduced in 2013. Furthermore, in OCC cable, the fiber’s transmission performance is completely unaffected, either by the fiber marking or cabling processes.
“We have concluded that the use of our fibers in OCC’s 24 pair cable results in a cabled attenuation matching the nominal value. We are confident that our ultra-low-loss fibers can contribute to achieve large capacity, high spectral efficiency and low power consumption in transoceanic networks,” said Dr. Masashi Onishi, General Manager at Optical Fiber and Cable division of Sumitomo Electric Industries Ltd.
“To support growing bandwidth, next generation subsea systems will offer Petabit-scale transmission. To achieve the required performance, cabling processes must capture the advantaged optical attenuation and large effective area of our ultra-low-loss fibers. OCC’s cabling process for 24 fiber pairs works with our high quality fiber to meet the challenge,” said Dr. Bernhard Deutsch, VP & GM, Optical Fiber & Cable, Corning Incorporated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318006059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
